Loos WJ - Search Results

1

Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins.

Loos WJ, Baker SD, Verweij J, Boonstra JG, Sparreboom A. Loos WJ, et al. Clin Pharmacol Ther. 2003 Oct;74(4):364-71. doi: 10.1016/S0009-9236(03)00222-4. Clin Pharmacol Ther. 2003. PMID: 14534523

2

Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel.

Engels FK, Ten Tije AJ, Baker SD, Lee CK, Loos WJ, Vulto AG, Verweij J, Sparreboom A. Engels FK, et al. Among authors: loos wj. Clin Pharmacol Ther. 2004 May;75(5):448-54. doi: 10.1016/j.clpt.2004.01.001. Clin Pharmacol Ther. 2004. PMID: 15116057 Clinical Trial.

3

Limited cerebrospinal fluid penetration of docetaxel.

ten Tije AJ, Loos WJ, Zhao M, Baker SD, Enting RH, van der Meulen H, Verweij J, Sparreboom A. ten Tije AJ, et al. Among authors: loos wj. Anticancer Drugs. 2004 Aug;15(7):715-8. doi: 10.1097/01.cad.0000136882.19552.8f. Anticancer Drugs. 2004. PMID: 15269603

4

Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel.

Engels FK, Mathot RA, Loos WJ, van Schaik RH, Verweij J. Engels FK, et al. Among authors: loos wj. Cancer Biol Ther. 2006 Jul;5(7):833-9. doi: 10.4161/cbt.5.7.2839. Epub 2006 Jul 22. Cancer Biol Ther. 2006. PMID: 16775418 Free article. Clinical Trial.

5

Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxel.

Engels FK, de Jong FA, Sparreboom A, Mathot RA, Loos WJ, Kitzen JJ, de Bruijn P, Verweij J, Mathijssen RH. Engels FK, et al. Among authors: loos wj. Oncologist. 2007 Mar;12(3):291-300. doi: 10.1634/theoncologist.12-3-291. Oncologist. 2007. PMID: 17405893 Free article.

6

The relevance of microdialysis for clinical on:cology.

Kitzen JJ, Verweij J, Wiemer EA, Loos WJ. Kitzen JJ, et al. Among authors: loos wj. Curr Clin Pharmacol. 2006 Sep;1(3):255-63. doi: 10.2174/157488406778249316. Curr Clin Pharmacol. 2006. PMID: 18666750 Review.

7

Determination of topotecan in human whole blood and unwashed erythrocytes by high-performance liquid chromatography.

Loos WJ, van Zomeren DM, Gelderblom H, Verweij J, Nooter K, Stoter G, Sparreboom A. Loos WJ, et al. J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Jan 5;766(1):99-105. doi: 10.1016/s0378-4347(01)00432-7. J Chromatogr B Analyt Technol Biomed Life Sci. 2002. PMID: 11820300

8

Phase I and pharmacologic study of liposomal lurtotecan, NX 211: urinary excretion predicts hematologic toxicity.

Kehrer DF, Bos AM, Verweij J, Groen HJ, Loos WJ, Sparreboom A, de Jonge MJ, Hamilton M, Cameron T, de Vries EG. Kehrer DF, et al. Among authors: loos wj. J Clin Oncol. 2002 Mar 1;20(5):1222-31. doi: 10.1200/JCO.2002.20.5.1222. J Clin Oncol. 2002. PMID: 11870164 Clinical Trial.

9

Structural identification and biological activity of 7-methyl-10,11-ethylenedioxy-20(S)-camptothecin, a photodegradant of lurtotecan.

Loos WJ, Verweij J, Kehrer DF, de Bruijn P, de Groot FM, Hamilton M, Nooter K, Stoter G, Sparreboom A. Loos WJ, et al. Clin Cancer Res. 2002 Mar;8(3):856-62. Clin Cancer Res. 2002. PMID: 11895919

10

Preclinical evaluation of alternative pharmaceutical delivery vehicles for paclitaxel.

Loos WJ, Szebeni J, ten Tije AJ, Verweij J, van Zomeren DM, Chung KN, Nooter K, Stoter G, Sparreboom A. Loos WJ, et al. Anticancer Drugs. 2002 Aug;13(7):767-75. doi: 10.1097/00001813-200208000-00012. Anticancer Drugs. 2002. PMID: 12187334

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

124 results

Search Page

Filters